Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ovarian Neoplasms

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 17 articles: HTML format

Single Articles

November 2023
1. WANG Y, Wen J, Sun X, Sun Y, et al
   CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms.
   Cancer Chemother Pharmacol. 2023 Nov 8. doi: 10.1007/s00280-023-04610.
   PubMed     Abstract available
   
   
   August 2023
2. NWABUFO CK
   Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
   Cancer Chemother Pharmacol. 2023 Aug 18. doi: 10.1007/s00280-023-04575.
   PubMed     Abstract available
   
   
   June 2023
3. KONIG P, Zhulenko R, Suparman E, Hoffmeister H, et al
   A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis.
   Cancer Chemother Pharmacol. 2023 Jun 5. doi: 10.1007/s00280-023-04548.
   PubMed     Abstract available
   
   
   
4. HONG L, Wang X, Zheng L, Wang S, et al
   Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis.
   Cancer Chemother Pharmacol. 2023 Jun 5. doi: 10.1007/s00280-023-04533.
   PubMed     Abstract available
   
   
   
5. HU C, Zhang Y, Pei T, Liu P, et al
   Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
   Cancer Chemother Pharmacol. 2023;91:523-529.
   PubMed     Abstract available
   
   
   March 2023
6. BAUM J, Zickler D, Bolbrinker J, Richter R, et al
   Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis.
   Cancer Chemother Pharmacol. 2023 Mar 22. doi: 10.1007/s00280-023-04514.
   PubMed     Abstract available
   
   
   
7. DE JONG LAW, Lambert M, van Erp NP, de Vries L, et al
   Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.
   Cancer Chemother Pharmacol. 2023 Mar 9. doi: 10.1007/s00280-023-04512.
   PubMed     Abstract available
   
   
   May 2022
8. MASSAI L, Messori L, Carpentieri A, Amoresano A, et al
   The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study.
   Cancer Chemother Pharmacol. 2022 May 11. pii: 10.1007/s00280-022-04438.
   PubMed     Abstract available
   
   
   April 2022
9. MANZO J, Puhalla S, Pahuja S, Ding F, et al
   A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
   Cancer Chemother Pharmacol. 2022 Apr 18. pii: 10.1007/s00280-022-04430.
   PubMed     Abstract available
   
   
   
10. XU J, Gao Y, Luan X, Li K, et al
    An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
    Cancer Chemother Pharmacol. 2022 Apr 13. pii: 10.1007/s00280-022-04403.
    PubMed     Abstract available
    
    
    
11. GREEN ML, Ma SC, Goble S, Giordano H, et al
    Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
    Cancer Chemother Pharmacol. 2022 Apr 10. pii: 10.1007/s00280-022-04413.
    PubMed     Abstract available
    
    
    October 2021
12. ROY P, Biswas S, Acharyya S, Dasgupta C, et al
    Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study.
    Cancer Chemother Pharmacol. 2021;88:731-740.
    PubMed     Abstract available
    
    
    July 2021
13. SUGISAWA N, Higuchi T, Han Q, Hozumi C, et al
    Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Cancer Chemother Pharmacol. 2021;88:61-67.
    PubMed     Abstract available
    
    
    June 2021
14. SOKOLENKO AP, Gorodnova TV, Bizin IV, Kuligina ES, et al
    Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
    Cancer Chemother Pharmacol. 2021 Jun 2. pii: 10.1007/s00280-021-04301.
    PubMed     Abstract available
    
    
    April 2021
15. VAULEON E, Behal H, Lebellec L, Desbarbieux R, et al
    Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study.
    Cancer Chemother Pharmacol. 2021;87:533-541.
    PubMed     Abstract available
    
    
    January 2021
16. LIU YK, Jia YJ, Liu SH, Ma J, et al
    FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-kappaB pathway.
    Cancer Chemother Pharmacol. 2021 Jan 3. pii: 10.1007/s00280-020-04215.
    PubMed     Abstract available
    
    
    October 2020
17. HANSEN MKG, Smerdel MP, Waldstrom M, Andersen RF, et al
    Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
    Cancer Chemother Pharmacol. 2020 Oct 16. pii: 10.1007/s00280-020-04162.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.